November 30, 2016 - By Hazel Jackson · 0 Comments
The stock of Corvus Pharmaceuticals Incorporated (NASDAQ:CRVS) registered an increase of 2.74% in short interest. CRVS’s total short interest was 198,500 shares in November as published by FINRA. Its up 2.74% from 193,200 shares, reported previously. With 12,100 shares average volume, it will take short sellers 16 days to cover their CRVS’s short positions. The short interest to Corvus Pharmaceuticals Incorporated’s float is 2.43%. The stock increased 1.01% or $0.15 on November 29, hitting $14.99. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has risen 8.47% since April 27, 2016 and is uptrending. It has outperformed by 3.24% the S&P500.
Corvus Pharmaceuticals, Inc. is a United States clinical-stage biopharmaceutical company. The company has a market cap of $300.12 million. The Firm focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. It currently has negative earnings. It is engaged in developing drugs designed to reprogram T-cells to restore the immune balance needed for tumor destruction.
More important recent Corvus Pharmaceuticals Inc (NASDAQ:CRVS) news were published by: Marketwatch.com which released: “Corvus Pharmaceuticals opens at $15 in market debut, priced at $15” on January 06, 2016, also Fiercebiotech.com published article titled: “Corvus Pharmaceuticals Completes $75 Million Series B Financing”, Globenewswire.com published: “Corvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual …” on July 06, 2016. More interesting news about Corvus Pharmaceuticals Inc (NASDAQ:CRVS) was released by: Bizjournals.com and their article: “Genentech partner makes 1st Bay Area biotech IPO filing of 2016” with publication date: January 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson